Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase

First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine

Nicole Bertoletti, Albert H. Chan, Raymond F. Schinazi, Yuhui Yin, Karen S. Anderson

Research output: Contribution to journalArticle

Abstract

The retrovirus HIV-1 has been a major health issue since its discovery in the early 80s. In 2017, over 37 million people were infected with HIV-1, of which 1.8 million were new infections that year. Currently, the most successful treatment regimen is the highly active antiretroviral therapy (HAART), which consists of a combination of three to four of the current 26 FDA-approved HIV-1 drugs. Half of these drugs target the reverse transcriptase (RT) enzyme that is essential for viral replication. One class of RT inhibitors is nucleoside reverse transcriptase inhibitors (NRTIs), a crucial component of the HAART. Once incorporated into DNA, NRTIs function as a chain terminator to stop viral DNA replication. Unfortunately, treatment with NRTIs is sometimes linked to toxicity caused by off-target side effects. NRTIs may also target the replicative human mitochondrial DNA polymerase (Pol γ), causing long-term severe drug toxicity. The goal of this work is to understand the discrimination mechanism of different NRTI analogues by RT. Crystal structures and kinetic experiments are essential for the rational design of new molecules that are able to bind selectively to RT and not Pol γ. Structural comparison of NRTI-binding modes with both RT and Pol γ enzymes highlights key amino acids that are responsible for the difference in affinity of these drugs to their targets. Therefore, the long-term goal of this research is to develop safer, next generation therapeutics that can overcome off-target toxicity.

Original languageEnglish (US)
Pages (from-to)1664-1675
Number of pages12
JournalProtein Science
Volume28
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Reverse Transcriptase Inhibitors
Lamivudine
RNA-Directed DNA Polymerase
Nucleosides
Crystal structure
Toxicity
HIV-1
Highly Active Antiretroviral Therapy
Pharmaceutical Preparations
Viral DNA
Retroviridae
DNA-Directed DNA Polymerase
Enzymes
triphosphoric acid
Emtricitabine
Human immunodeficiency virus 1 reverse transcriptase
lamivudine triphosphate
Drug-Related Side Effects and Adverse Reactions
DNA Replication
Mitochondrial DNA

Keywords

  • emtricitabine
  • inhibitor–protein complexes
  • lamivudine
  • macromolecular X-ray crystallography
  • nucleoside reverse transcriptase inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase : First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. / Bertoletti, Nicole; Chan, Albert H.; Schinazi, Raymond F.; Yin, Yuhui; Anderson, Karen S.

In: Protein Science, Vol. 28, No. 9, 01.01.2019, p. 1664-1675.

Research output: Contribution to journalArticle

@article{2a8e0decff624094baa1084fc905aeb4,
title = "Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine",
abstract = "The retrovirus HIV-1 has been a major health issue since its discovery in the early 80s. In 2017, over 37 million people were infected with HIV-1, of which 1.8 million were new infections that year. Currently, the most successful treatment regimen is the highly active antiretroviral therapy (HAART), which consists of a combination of three to four of the current 26 FDA-approved HIV-1 drugs. Half of these drugs target the reverse transcriptase (RT) enzyme that is essential for viral replication. One class of RT inhibitors is nucleoside reverse transcriptase inhibitors (NRTIs), a crucial component of the HAART. Once incorporated into DNA, NRTIs function as a chain terminator to stop viral DNA replication. Unfortunately, treatment with NRTIs is sometimes linked to toxicity caused by off-target side effects. NRTIs may also target the replicative human mitochondrial DNA polymerase (Pol γ), causing long-term severe drug toxicity. The goal of this work is to understand the discrimination mechanism of different NRTI analogues by RT. Crystal structures and kinetic experiments are essential for the rational design of new molecules that are able to bind selectively to RT and not Pol γ. Structural comparison of NRTI-binding modes with both RT and Pol γ enzymes highlights key amino acids that are responsible for the difference in affinity of these drugs to their targets. Therefore, the long-term goal of this research is to develop safer, next generation therapeutics that can overcome off-target toxicity.",
keywords = "emtricitabine, inhibitor–protein complexes, lamivudine, macromolecular X-ray crystallography, nucleoside reverse transcriptase inhibitors",
author = "Nicole Bertoletti and Chan, {Albert H.} and Schinazi, {Raymond F.} and Yuhui Yin and Anderson, {Karen S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/pro.3681",
language = "English (US)",
volume = "28",
pages = "1664--1675",
journal = "Protein Science",
issn = "0961-8368",
publisher = "Cold Spring Harbor Laboratory Press",
number = "9",

}

TY - JOUR

T1 - Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase

T2 - First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine

AU - Bertoletti, Nicole

AU - Chan, Albert H.

AU - Schinazi, Raymond F.

AU - Yin, Yuhui

AU - Anderson, Karen S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The retrovirus HIV-1 has been a major health issue since its discovery in the early 80s. In 2017, over 37 million people were infected with HIV-1, of which 1.8 million were new infections that year. Currently, the most successful treatment regimen is the highly active antiretroviral therapy (HAART), which consists of a combination of three to four of the current 26 FDA-approved HIV-1 drugs. Half of these drugs target the reverse transcriptase (RT) enzyme that is essential for viral replication. One class of RT inhibitors is nucleoside reverse transcriptase inhibitors (NRTIs), a crucial component of the HAART. Once incorporated into DNA, NRTIs function as a chain terminator to stop viral DNA replication. Unfortunately, treatment with NRTIs is sometimes linked to toxicity caused by off-target side effects. NRTIs may also target the replicative human mitochondrial DNA polymerase (Pol γ), causing long-term severe drug toxicity. The goal of this work is to understand the discrimination mechanism of different NRTI analogues by RT. Crystal structures and kinetic experiments are essential for the rational design of new molecules that are able to bind selectively to RT and not Pol γ. Structural comparison of NRTI-binding modes with both RT and Pol γ enzymes highlights key amino acids that are responsible for the difference in affinity of these drugs to their targets. Therefore, the long-term goal of this research is to develop safer, next generation therapeutics that can overcome off-target toxicity.

AB - The retrovirus HIV-1 has been a major health issue since its discovery in the early 80s. In 2017, over 37 million people were infected with HIV-1, of which 1.8 million were new infections that year. Currently, the most successful treatment regimen is the highly active antiretroviral therapy (HAART), which consists of a combination of three to four of the current 26 FDA-approved HIV-1 drugs. Half of these drugs target the reverse transcriptase (RT) enzyme that is essential for viral replication. One class of RT inhibitors is nucleoside reverse transcriptase inhibitors (NRTIs), a crucial component of the HAART. Once incorporated into DNA, NRTIs function as a chain terminator to stop viral DNA replication. Unfortunately, treatment with NRTIs is sometimes linked to toxicity caused by off-target side effects. NRTIs may also target the replicative human mitochondrial DNA polymerase (Pol γ), causing long-term severe drug toxicity. The goal of this work is to understand the discrimination mechanism of different NRTI analogues by RT. Crystal structures and kinetic experiments are essential for the rational design of new molecules that are able to bind selectively to RT and not Pol γ. Structural comparison of NRTI-binding modes with both RT and Pol γ enzymes highlights key amino acids that are responsible for the difference in affinity of these drugs to their targets. Therefore, the long-term goal of this research is to develop safer, next generation therapeutics that can overcome off-target toxicity.

KW - emtricitabine

KW - inhibitor–protein complexes

KW - lamivudine

KW - macromolecular X-ray crystallography

KW - nucleoside reverse transcriptase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85070700646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070700646&partnerID=8YFLogxK

U2 - 10.1002/pro.3681

DO - 10.1002/pro.3681

M3 - Article

VL - 28

SP - 1664

EP - 1675

JO - Protein Science

JF - Protein Science

SN - 0961-8368

IS - 9

ER -